uniQure (NASDAQ:QURE) Trading Down 8.3% – Here’s Why

Shares of uniQure N.V. (NASDAQ:QURE) dropped 8.3% during mid-day trading on Friday . The stock traded as low as $15.76 and last traded at $15.54. Approximately 700,811 shares traded hands during trading, a decline of 81% from the average daily volume of 3,615,214 shares. The stock had previously closed at $16.94.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintains a $70 target on QURE (an upbeat signal from a sell‑side supporter, but note the firm also lowered near‑term estimates). Read More.
• Neutral Sentiment: Investment commentary/analysis pieces are circulating (e.g., Seeking Alpha) that frame uniQure’s situation as complex — useful for context but not an immediate catalyst by themselves. Read More.
• Negative Sentiment: A wave of shareholder‑rights firms have announced or reminded investors about securities class‑action litigation and an April 13, 2026 lead‑plaintiff deadline; that increases legal and settlement risk and is pressuring sentiment. Representative notices from Schall, Faruqi & Faruqi, Pomerantz, Rosen and others have been published. Read More.
• Negative Sentiment: Hagens Berman and media reports say the FDA publicly rebuked uniQure — reportedly accusing the company of pushing “distorted” or “manipulated” data for its failed AMT‑130 gene‑therapy program. An FDA rebuke tied to clinical data integrity is a material regulatory and reputational negative. Read More.
• Negative Sentiment: HC Wainwright significantly lowered near‑term and multi‑year EPS forecasts for uniQure (Q1–Q4 2026 and FY2026–FY2029 estimates were cut), which reduces near‑term fundamental expectations even though the firm kept a Buy rating. Read More.

Analysts Set New Price Targets

Several research firms recently weighed in on QURE. The Goldman Sachs Group reduced their target price on uniQure from $37.00 to $9.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 3rd. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Barclays began coverage on shares of uniQure in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price objective for the company. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Finally, Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $12.00 to $35.00 in a report on Wednesday. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, uniQure has an average rating of “Moderate Buy” and an average price target of $43.25.

uniQure Price Performance

The company has a market capitalization of $953.27 million, a price-to-earnings ratio of -4.40 and a beta of 0.73. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The company has a 50 day simple moving average of $21.53 and a 200 day simple moving average of $29.49.

uniQure (NASDAQ:QURE) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. As a group, research analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Insider Activity at uniQure

In related news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeannette Potts sold 3,412 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the sale, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 81,399 shares of company stock valued at $1,527,645 over the last quarter. Company insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of large investors have recently modified their holdings of QURE. Private Trust Co. NA acquired a new position in uniQure during the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp grew its position in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new stake in shares of uniQure during the third quarter valued at approximately $50,000. Torren Management LLC acquired a new position in shares of uniQure during the fourth quarter worth $28,000. Finally, FNY Investment Advisers LLC boosted its stake in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.